Long-term survivors with immunotherapy in advanced NSCLC: is 'cure' within reach?

被引：5
作者：
Monteverdi, Sara [1 ]
Vita, Emanuele [2 ]
Sartori, Giulia [1 ]
Ferrara, Miriam Grazia [2 ]
D'Argento, Ettore [3 ]
Tortora, Giampaolo [2 ,3 ]
Milella, Michele [1 ]
Bria, Emilio [2 ,3 ]
Pilotto, Sara [1 ]
机构：
[1] Univ Verona, Azienda Osped Univ Integrata, UOC Oncol, Verona, Italy
[2] Univ Cattolica Sacro Cuore, Med Oncol, Rome, Italy
[3] Fdn Policlin Univ Agostino Gemelli IRCC, Comprehens Canc Ctr, Rome, Italy
来源：
TRANSLATIONAL CANCER RESEARCH | 2020年 / 9卷 / 02期
关键词：
PEMBROLIZUMAB; CHEMOTHERAPY;
D O I：
10.21037/tcr.2019.12.82
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：409 / 414
页数：6
相关论文
共 25 条
  • [1] [Anonymous], 2019, J CLIN ONCOL S
  • [2] [Anonymous], ANN ONCOL S8
  • [3] Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis
    Dafni, Urania
    Tsourti, Zoi
    Vervita, Katerina
    Peters, Solange
    [J]. LUNG CANCER, 2019, 134 : 127 - 140
  • [4] Outcomes among patients (pts) with metastatic nonsquamous NSCLC with liver metastases or brain metastases treated with pembrolizumab (pembro) plus pemetrexed-platinum: Results from the KEYNOTE-189 study
    Garassino, Marina C.
    Gadgeel, Shirish
    Esteban, Emilio
    Felip, Enriqueta
    Speranza, Giovanna
    De Angelis, Flavia
    Domine, Manuel
    Clingan, Philip
    Hochmair, Maximilian J.
    Powell, Steven F.
    Cheng, Susanna Y. -S.
    Bischoff, Helge G.
    Peled, Nir
    Grossi, Francesco
    Jennens, Ross R.
    Reck, Martin
    Hui, Rina
    Garon, Edward B.
    Boyer, Michael
    Rubio-Viqueira, Belen
    Novello, Silvia
    Kurata, Takayasu
    Gray, Jhanelle E.
    Cardellino, Anna
    Yang, Jing
    Pietanza, M. Catherine
    Rodriguez-Abreu, Delvys
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [5] Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
    Garon, Edward B.
    Hellmann, Matthew D.
    Rizvi, Naiyer A.
    Carcereny, Enric
    Leighl, Natasha B.
    Ahn, Myung-Ju
    Eder, Joseph Paul
    Balmanoukian, Ani S.
    Aggarwal, Charu
    Horn, Leora
    Patnaik, Amita
    Gubens, Matthew
    Ramalingam, Suresh S.
    Felip, Enriqueta
    Goldman, Jonathan W.
    Scalzo, Cathie
    Jensen, Erin
    Kush, Debra A.
    Hui, Rina
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (28) : 2518 - +
  • [6] Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
    Garon, Edward B.
    Rizvi, Naiyer A.
    Hui, Rina
    Leighl, Natasha
    Balmanoukian, Ani S.
    Eder, Joseph Paul
    Patnaik, Amita
    Aggarwal, Charu
    Gubens, Matthew
    Horn, Leora
    Carcereny, Enric
    Ahn, Myung-Ju
    Felip, Enriqueta
    Lee, Jong-Seok
    Hellmann, Matthew D.
    Hamid, Omid
    Goldman, Jonathan W.
    Soria, Jean-Charles
    Dolled-Filhart, Marisa
    Rutledge, Ruth Z.
    Zhang, Jin
    Lunceford, Jared K.
    Rangwala, Reshma
    Lubiniecki, Gregory M.
    Roach, Charlotte
    Emancipator, Kenneth
    Gandhi, Leena
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (21) : 2018 - 2028
  • [7] Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC
    Gettinger, S.
    Borghaei, H.
    Brahmer, J.
    Chow, L.
    Burgio, M.
    De Castro Carpeno, J.
    Pluzanski, A.
    Arrieta, O.
    Aren Frontera, O.
    Chiari, R.
    Butts, C.
    Wojcik-Tomaszewska, J.
    Coudert, B.
    Garassino, M.
    Ready, N.
    Felip, E.
    Alonso Garcia, M.
    Waterhouse, D.
    Domine, M.
    Barlesi, F.
    Antonia, S.
    Wohlleber, M.
    Gerber, D.
    Czyzewicz, G.
    Spigel, D.
    Crino, L.
    Eberhardt, W.
    Li, A.
    Marimuthu, S.
    Vokes, E.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S244 - S245
  • [8] Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
    Hellmann, M. D.
    Paz-Ares, L.
    Bernabe Caro, R.
    Zurawski, B.
    Kim, S. -W.
    Carcereny Costa, E.
    Park, K.
    Alexandru, A.
    Lupinacci, L.
    de la Mora Jimenez, E.
    Sakai, H.
    Albert, I.
    Vergnenegre, A.
    Peters, S.
    Syrigos, K.
    Barlesi, F.
    Reck, M.
    Borghaei, H.
    Brahmer, J. R.
    O'Byrne, K. J.
    Geese, W. J.
    Bhagavatheeswaran, P.
    Rabindran, S. K.
    Kasinathan, R. S.
    Nathan, F. E.
    Ramalingam, S. S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) : 2020 - 2031
  • [9] Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
    Hellmann, M. D.
    Ciuleanu, T. -E.
    Pluzanski, A.
    Lee, J. S.
    Otterson, G. A.
    Audigier-Valette, C.
    Minenza, E.
    Linardou, H.
    Burgers, S.
    Salman, P.
    Borghaei, H.
    Ramalingam, S. S.
    Brahmer, J.
    Reck, M.
    O'Byrne, K. J.
    Geese, W. J.
    Green, G.
    Chang, H.
    Szustakowski, J.
    Bhagavatheeswaran, P.
    Healey, D.
    Fu, Y.
    Nathan, F.
    Paz-Ares, L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) : 2093 - 2104
  • [10] IMpower131: Final OS Results of Carboplatin plus Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC
    Jotte, R.
    Cappuzzo, F.
    Vynnychenko, I.
    Stroyakovskiy, D.
    Rodriguez Abreu, D.
    Hussein, M.
    Soo, R.
    Conter, H.
    Kozuki, T.
    Huang, K.
    Graupner, V.
    Sun, S.
    Hoang, T.
    Jessop, H.
    Mccleland, M.
    Ballinger, M.
    Sandler, A.
    Socinski, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S243 - S244
123